NEW YORK, March 7 (GenomeWeb News) - UK-based Solexa and Lynx Therapeutics of Hayward, Calif., have completed their previously announced merger, the companies said today.
The combined company, which will be called Solexa, is incorporated in Delawareand will start trading today on the Nasdaq SmallCap Market under the symbol SLXA. The company's UKoperation has become a wholly owned subsidiary, the firms said.
Solexa said it plans to launch its first product, a gene-analysis platform based on sequencing-by-synthesis and micorarrays, by the end of the year. Initially, the company will focus on the research market.
